SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and ...
Good day, and thank you for standing by. Welcome to the second-quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there ...
Thank you for standing by and welcome to the Fourth Quarter 2021 Codex DNA Earnings Conference Call. [Operator Instructions] I would now like to hand the conference to our Director of Investor ...
-- Acquisition will allow Codex DNA to expand its commercial BioXp™ system and biofoundry service offerings, reduce raw material costs, and accelerate overall growth strategy -- SAN DIEGO, Nov. 09, ...
The company's share price blasted 39% higher because of an exciting new partnership. Under the terms of the deal, the two companies will work together to further develop Codex DNA's BioXP, which its ...
Codex DNA, fresh off raising $122 million in an initial public stock offering in June, has inked a deal to buy privately held Eton Bioscience — combining two of San Diego’s synthetic biology tools and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results